Cao et al., 2022 - Google Patents
Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapyCao et al., 2022
View PDF- Document ID
- 3734544718467524768
- Author
- Cao X
- Chen J
- Li B
- Dang J
- Zhang W
- Zhong X
- Wang C
- Raoof M
- Sun Z
- Yu J
- Fakih M
- Feng M
- Publication year
- Publication venue
- Science advances
External Links
Snippet
Macrophages are essential in eliciting antibody-dependent cellular phagocytosis (ADCP) of cancer cells. However, a satisfactory anticancer efficacy of ADCP is contingent on early antibody administration, and resistance develops along with cancer progression. Here, we …
- 210000002540 Macrophages 0 title abstract description 183
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy | |
| Du et al. | Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells | |
| Zahnreich et al. | Childhood cancer: occurrence, treatment and risk of second primary malignancies | |
| Lu et al. | Complement signals determine opposite effects of B cells in chemotherapy-induced immunity | |
| Yu et al. | Plexin-B2 mediates physiologic and pathologic functions of angiogenin | |
| Chen et al. | Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells | |
| Lee et al. | Phase I trial of expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers | |
| Poh et al. | Inhibition of hematopoietic cell kinase activity suppresses myeloid cell-mediated colon cancer progression | |
| Weinstein et al. | Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies | |
| Thieblemont et al. | Optimizing therapy for nodal marginal zone lymphoma | |
| Noubade et al. | NRROS negatively regulates reactive oxygen species during host defence and autoimmunity | |
| Szydlowski et al. | FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas | |
| Liu et al. | CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition | |
| Salerno et al. | Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity | |
| Lee et al. | Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+ CD25+ regulatory T cells | |
| Herrmann et al. | The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38-AML progenitor cells | |
| Song et al. | The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity | |
| Thieblemont | Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma | |
| Drouin et al. | CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy | |
| Cho et al. | A novel combination treatment targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified colorectal cancers | |
| Wang et al. | The deposition of N otch1 in hepatitis B virus‐associated nephropathy and its role in hepatitis B virus X protein‐induced epithelial–mesenchymal transdifferentiation and immunity disorder in renal tubular epithelial cells | |
| Mannavola et al. | An Italian retrospective survey on bone metastasis in melanoma: impact of immunotherapy and radiotherapy on survival | |
| WO2016104777A1 (en) | Method for treating cancer | |
| Krueger et al. | Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy | |
| Wang et al. | Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer |